Journal of Leukemia & Lymphoma 2018;27(12):716-720,724

doi:10.3760/cma.j.issn.1009-9921.2018.12.004

Treatment progress of relapsed/refractory diffuse large B-cell lymphoma

Jiaqi QIN 1 ; Wei XU

Affiliations

+expand

Keywords

Lymphoma,large B-cell,diffuse; Recurrence; Refractory; Treatment; American Society of Hematology annual meeting

Country

China

Language

Chinese

Abstract

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy and who are not candidates for stem cell transplantation have limited effective treatment options, resulting in a poor prognosis, thus, treatments with novel mechanisms of action are urgently needed. In the 60th American Society of Hematology (ASH) Annual Meeting, detailed reports focused on the research progresses of single agent, drug combination and chimeric antigen receptor T cell (CAR-T) therapy, providing more treatment options for R/R DLBCL patients.